Every year, the Ragan PR Daily Awards recognize the most outstanding public relations campaigns and initiatives. Due to the ACR’s work to elevate the voices of patients living with rheumatic diseases, its 2020 Rheumatic Diseases Awareness Month campaign has received three of these major awards.
Early 2022’s Awards, Appointments & Announcements in Rheumatology
Alvin Wells, MD, PhD, Appointed Director for Department of Rheumatology, Advocate Aurora Healthcare Medical Group In July, Alvin F. Wells, MD, PhD, was named director of the Department of Rheumatology for the Advocate Aurora Healthcare Medical Group of Wisconsin. Dr. Wells, who holds faculty appointments at Marquette University, MCOW, Duke University, Durham, N.C., and the…
Improving Lupus Drug Regimen Adherence Among Minorities
Rheumatologists can do better at helping systemic lupus erythematosus patients from racial and ethnic minority groups adhere to their lupus medication regimens, according to a paper published in Arthritis Care & Research. Researchers from Duke University examined medication adherence barriers from the perspectives of healthcare providers and patients. Their findings suggest more attention should be…
The ACR Is Instituting a New Governance Structure
In The Will to Govern Well, Glenn Tecker and co‐authors suggest that for associations, the term “governance” refers to “the decision‐making units of the organization and [the] relative powers, authorities, and responsibilities that each possesses, as well as … the composition of each unit and how individuals are selected to participate in each.” In 2019,…
Prior Authorization Is Under Review
I just couldn’t believe it. Like all of you, I receive many requests to see patients urgently. And like all of you, I can’t possibly accommodate all of those requests. So I triage: I look through the referrals and try to differentiate patients who want to be seen from those who need to be seen….
Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…
Clinical Insights into Gout Management: Q&A with Dr. Tuhina Neogi
Gout affects more than 9.2 million adults in the U.S. and is the most common form of inflammatory arthritis. This condition and its complications are painful and potentially disabling with varying risk factors. It is characterized by symptoms that are usually sudden, with intense episodes of painful swelling in one or more joints, most often…
Research on Diet & Gout
According to research from Yokose et al. presented at ACR Convergence 2021, regardless of genetic predisposition, diet influences a person’s risk of developing gout.1 Several recent analyses of the Global Burden of Disease (GBD) Study report a disproportionate worsening of gout burden among women, suggesting intensive dietary measures for gout prevention are indicated, especially in…
An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report
According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.
Targeting Disease-Causing Cells: RheumMadness 2022 Chimeric Antigen Receptor T Cells Scouting Report
CD19 chimeric antigen receptor T (CAR-T) cell therapies may have the potential to treat rheumatic diseases in which current therapeutic options are limited, such as lupus, interstitial lung disease and systemic sclerosis.
- « Previous Page
- 1
- …
- 102
- 103
- 104
- 105
- 106
- …
- 805
- Next Page »